Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model

Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come from its ability to modify the tumour microenvironment by targeting homologous recombination...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Borst, Gerben R., Kumareswaran, Ramya, Yücel, Hatice, Telli, Seyda, Do, Trevor, McKee, Trevor, Zafarana, Gaetano, Jonkers, Jos, Verheij, Marcel, O’Connor, Mark J., Rottenberg, Sven, Bristow, Robert G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2017
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5675659/
https://ncbi.nlm.nih.gov/pubmed/29152107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20936
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia